Skip to main content

Table 1 Clinical characteristics of β-amyloid positivity converters and non-converters

From: Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals

  ADNI dataset SMC dataset p-value
Total Converter Nonconverter p-value Total Converter Nonconverter p-value
Subjects, N (%) 229 (100.0) 53 (23.1) 176 (75.1) - 40 (100.0) 10 (25.0) 30 (75.0) - -
Follow-up duration (years) 7.1 (1.7) 5.7 (2.2) 7.5 (1.3) <0.001* 6.1 (2.0) 3.9 (1.2) 6.7 (1.6) <0.001* <0.001*
Age, mean years (SD) 71.7 (7.3) 72.9 (6.8) 71.3 (7.5) 0.163 70.1 (7.7) 75.0 (8.1) 69.5 (7.3) 0.050 0.498
Female, N (%) 108 (47.2) 23 (43.4) 85 (48.3) 0.639 28 (68.3) 7 (70.0) 20 (67.7) 1.000 0.028*
APOE ε4 carriers, N (%) 54 (23.6) 20 (37.7) 34 (19.3) 0.010* 5 (12.5) 3 (30.0) 2 (6.7) 0.168 0.175
Education, years (SD) 16.5 (2.7) 16.6 (2.3) 16.5 (2.8) 0.813 9.0 (4.6) 11.2 (4.2) 8.3 (4.6) 0.087 <0.001*
Family history, N (%) 124 (54.1) 31 (58.4) 93 (52.8) 0.571 10 (24.4) 4 (40.0) 6 (19.4) 0.369 0.001*
Amyloid tracer uptakea, mean (SD) 1.017 (0.054) 1.058 (0.039) 1.005 (0.052) <0.001* 3.377 (7.325) 12.052 (5.492) 0.088 (4.754) <0.001* -
  1. ADNI Alzheimer’s Disease Neuroimaging Initiative, SMC Samsung Medical Center, SD standard deviation, APOE ε4 apolipoprotein E ε4, SUVR standardized uptake value ratios, AD Alzheimer’s disease
  2. Comparisons between cohorts
  3. aValues represent global SUVR in the ADNI dataset and global Centiloid in the SMC dataset
  4. *Statistically significant (p < 0.05)